Last Published 10.31.2025 Effective Date: 11.01.2025 This policy addresses the use of C1 esterace inhibitors (human), C1 esterace inhibitors (recombinant), and plasma kallikrein inhibitors (human) for the treatment and prophlaxis of hereditary angioedema (HAE)
Ipamorelin, a selective growth hormone secretagogue, supports this action without causing unwanted increases in cortisol or prolactin
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Stress reduction may also play a role, as chronic psychological stress and elevated cortisol levels can impair metabolic hormone regulation
Combination therapy is evaluated on a case-by-case basis, considering medical history, goals, and response to treatment
View training Contact Us Get In Touch With Us Experience expert care tailored to you